Publication:

Oral cancer chemoprevention: COX-2 inhibitor a covenant

Oral cancer survival remains poor despite advancement in treatment modalities. In oral cancer and oral premalignant lesions, cyclooxygenase-2 (COX-2) is widely expressed and tends to be enhanced especially in high-risk oral lesions. Numerous researches suggests that the inflammation pathway of cyclooxygenase/prostaglandin E2 (PGE2) leads to the development and progression of a number of cancers, including oral squamous cell carcinoma (OSCC). With an emphasis on research data, this article discusses the relationship between inflammation and cancer, summarizes the use of anti-inflammatory agents COX-2 inhibitors for cancer chemoprevention and treatment, and explains the mechanisms underlying the anti-cancer effects of anti-inflammatory agents (COX-2 inhibitors).